Abstract The invention pertains to a probiotic agent designed to modulate the gut hormone GLP-1 levels, encompassing the Lacticaseibacillus rhamnosus LRa05 strain (CGMCC No.1.12734) and its application in obesity treatment. The LRa05 strain significantly enhances GLP-1 expression in intestinal endocrine cells, reducing body weight and serum ALT and AST levels in obese individuals....